AI Article Synopsis
- The study investigates the relationship between statins, testosterone replacement therapy (TTh), and cardiovascular disease (CVD) among men, comparing those with hormone-related cancers (HRCa) to cancer-free individuals.
- A large sample of 44,330 men was analyzed, revealing that both statins and TTh were independently linked to a lower incidence of CVD, especially when used together, although TTh alone didn't show the same effect for HRCa survivors.
- The findings suggest that pre-diagnostic use of statins and TTh reduces the risk of CVD, warranting further investigation into specific cardiovascular outcomes for those with a history of hormone-related cancers.
Article Abstract
Purpose: Statins and testosterone replacement therapy (TTh) have been previously linked with prostate, colorectal and male breast cancer (hereinafter we will refer as hormone related cancers [HRCa]), and cardiovascular disease (CVD). However, there is a poor understanding about the combined association of statins and TTh with incident CVD among HRCa survivors and a matched cancer-free cohort.
Methods: We identified 44,330 men of whom 22,165 were previously diagnosed with HRCa, and 22,165 were age-and index-matched cancer-free in SEER-Medicare 2007-2015. Pre-diagnostic prescription of statins and TTh prior to CVD development was ascertained for this analysis in the two matched cohorts. Weighted multivariable-adjusted conditional logistic regression models were used to evaluate the independent and combined associations of statins and TTh with CVD.
Results: We found that use of statins (OR = 0.51, 95% CI: 0.46-0.55) and TTh (OR = 0.81, 95% CI: 0.67-0.97) were each independently inversely associated with incident CVD in the overall sample. TTh plus statins was also inversely associated with CVD. Associations were similar in the matched cancer-free cohort. Among HRCa survivors, only statins and combination of TTh plus statins (OR = 0.60, 95% CI: 0.44-0.98) were inversely associated with CVD, but the independent use of TTh was not associated with CVD.
Conclusion: In general, pre-diagnostic use of statins and TTh, prior to CVD development, independently or in combination, were inversely associated with CVD in the overall, cancer-free population, and among HRCa survivors (mainly combination). Independent effects and combination of statins and TTh remained to be confirmed with specific CVD outcomes among HRCa survivors.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10635393 | PMC |
| http://dx.doi.org/10.21203/rs.3.rs-3530181/v1 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Incidence of prostate, colorectal and male breast cancers in relation with statins and testosterone replacement therapy: SEER-Medicare 2007-2015.
Cancer Epidemiol
October 2024
School of Public and Population Health, University of Texas Medical Branch, Galveston, TX, USA.
Introduction: Statins and testosterone replacement therapy (TTh) have been inconsistently associated with a reduced risk of hormone-related cancers (HRCs, prostate [PCa], colorectal [CRC], and male breast cancers [BrCa]). Yet, the joint association of statins and TTh with the incidence of these cancers, and whether these associations vary by race, remains poorly understood. The objective of this retrospective cohort study is to examine the independent and joint effects of pre-diagnostic use of statins and TTh on the risk of HRCs, including PCa, CRC, and male BrCa.
View Article and Find Full Text PDFArticle Synopsis
- The study investigates the relationship between statins, testosterone replacement therapy (TTh), and cardiovascular disease (CVD) among men, comparing those with hormone-related cancers (HRCa) to cancer-free individuals.
- A large sample of 44,330 men was analyzed, revealing that both statins and TTh were independently linked to a lower incidence of CVD, especially when used together, although TTh alone didn't show the same effect for HRCa survivors.
- The findings suggest that pre-diagnostic use of statins and TTh reduces the risk of CVD, warranting further investigation into specific cardiovascular outcomes for those with a history of hormone-related cancers.
Joint association of statins and testosterone replacement therapy with cardiovascular disease among older men with prostate cancer: SEER-Medicare 2007-2015.
Cancer Epidemiol
August 2022
Division of Urology, UTHealth McGovern Medical School, Houston, TX, USA.
Background: Use of statins and testosterone replacement therapy (TTh) have been independently linked with prostate cancer (PCa) and cardiovascular diseases (CVD). However, there is a research gap about the joint association of statins and TTh with CVD among PCa survivors and a matched cancer-free cohort.
Methods: In SEER-Medicare 2007-2015 (N = 35,990 men), we identified 17,995 PCa survivors, and 17,995 age- and index-matched cancer-free men.
The role of testosterone replacement therapy and statin use, and their combination, in prostate cancer.
Cancer Causes Control
September 2021
Deparment of Preventive Medicine and Population Health, University of Texas Medical Branch, Galveston, TX, USA.
Purpose: Previous studies have reported conflicting results in the associations of testosterone replacement therapy (TTh) and statins use with prostate cancer (PCa). However, the combination of these treatments with PCa stage and grade at diagnosis and prostate cancer-specific mortality (PCSM) and by race/ethnicity remains unclear.
Methods: We identified non-Hispanic White (NHW, N = 58,576), non-Hispanic Black (NHB, n = 9,703) and Hispanic (n = 4,898) men diagnosed with PCa in SEER-Medicare data 2007-2011.
Independent and Joint Effects of Testosterone Replacement Therapy and Statins use on the Risk of Prostate Cancer Among White, Black, and Hispanic Men.
Cancer Prev Res (Phila)
July 2021
Division of Urology, UTHealth McGovern Medical School, Houston, Texas.
The associations of testosterone therapy (TTh) and statins use with prostate cancer remain conflicted. However, the joint effects of TTh and statins use on the incidence of prostate cancer, stage and grade at diagnosis, and prostate cancer-specific mortality (PCSM) have not been studied.We identified White ( = 74,181), Black ( = 9,157), and Hispanic ( = 3,313) men diagnosed with prostate cancer in SEER-Medicare 2007-2016.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!